Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT522 + Rituximab in R/R B-Cell Lymphoma
NCT05950334Phase 1Completed
- Sponsor
- Fate Therapeutics
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT522 in B cell lymphoma (2 arms), sponsored by Fate Therapeutics. Primary endpoints: Dose Limiting Toxicities and Severity of Dose Limiting Toxicities. Started Nov 2023; status: completed.
02
Drugs
FT522
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05950334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950334.